Drug delivering technology for endovascular management of infrainguinal peripheral artery disease

Karan Sarode, David A. Spelber, Deepak L. Bhatt, Atif Mohammad, Anand Prasad, Emmanouil S. Brilakis, Subhash Banerjee

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Endovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, mid- and long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials investigating the use of drug-coated stents and drug-coated balloons indicate a significant improvement in endovascular treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery disease. Additionally, it provides an overview of the development of this technology, highlights landmark ongoing and completed clinical trials, examines evidence to support the use of drug-coated technologies in combination with other modalities, and examines promising new technological developments. Last, it summarizes the challenges and safety concerns that have delayed U.S. Food and Drug Administration approval of these devices.

Original languageEnglish (US)
Pages (from-to)827-839
Number of pages13
JournalJACC: Cardiovascular Interventions
Volume7
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Peripheral Arterial Disease
Technology
Drug-Eluting Stents
Pharmaceutical Preparations
Stents
Device Approval
Clinical Trials
Inventions
Balloon Angioplasty
Therapeutics
Metals
Safety

Keywords

  • drug-coated balloons
  • drug-coated stents
  • peripheral artery disease
  • review

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. / Sarode, Karan; Spelber, David A.; Bhatt, Deepak L.; Mohammad, Atif; Prasad, Anand; Brilakis, Emmanouil S.; Banerjee, Subhash.

In: JACC: Cardiovascular Interventions, Vol. 7, No. 8, 2014, p. 827-839.

Research output: Contribution to journalArticle

Sarode, Karan ; Spelber, David A. ; Bhatt, Deepak L. ; Mohammad, Atif ; Prasad, Anand ; Brilakis, Emmanouil S. ; Banerjee, Subhash. / Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. In: JACC: Cardiovascular Interventions. 2014 ; Vol. 7, No. 8. pp. 827-839.
@article{a5b174f28e58443f9f2da542f1499812,
title = "Drug delivering technology for endovascular management of infrainguinal peripheral artery disease",
abstract = "Endovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, mid- and long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials investigating the use of drug-coated stents and drug-coated balloons indicate a significant improvement in endovascular treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery disease. Additionally, it provides an overview of the development of this technology, highlights landmark ongoing and completed clinical trials, examines evidence to support the use of drug-coated technologies in combination with other modalities, and examines promising new technological developments. Last, it summarizes the challenges and safety concerns that have delayed U.S. Food and Drug Administration approval of these devices.",
keywords = "drug-coated balloons, drug-coated stents, peripheral artery disease, review",
author = "Karan Sarode and Spelber, {David A.} and Bhatt, {Deepak L.} and Atif Mohammad and Anand Prasad and Brilakis, {Emmanouil S.} and Subhash Banerjee",
year = "2014",
doi = "10.1016/j.jcin.2014.05.008",
language = "English (US)",
volume = "7",
pages = "827--839",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Drug delivering technology for endovascular management of infrainguinal peripheral artery disease

AU - Sarode, Karan

AU - Spelber, David A.

AU - Bhatt, Deepak L.

AU - Mohammad, Atif

AU - Prasad, Anand

AU - Brilakis, Emmanouil S.

AU - Banerjee, Subhash

PY - 2014

Y1 - 2014

N2 - Endovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, mid- and long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials investigating the use of drug-coated stents and drug-coated balloons indicate a significant improvement in endovascular treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery disease. Additionally, it provides an overview of the development of this technology, highlights landmark ongoing and completed clinical trials, examines evidence to support the use of drug-coated technologies in combination with other modalities, and examines promising new technological developments. Last, it summarizes the challenges and safety concerns that have delayed U.S. Food and Drug Administration approval of these devices.

AB - Endovascular intervention has become a well-recognized treatment modality for peripheral artery disease; however, mid- and long-term outcomes have been plagued by limited durability. Plain balloon angioplasty and bare-metal stents have historically suffered from high restenosis rates leading to the need for frequent repeat revascularization procedures. The innovation of locally administered, drug-delivering balloons and stents has been a direct result of technological innovations directed toward prevention and treatment of this limitation. Over the last 5 years, numerous clinical trials investigating the use of drug-coated stents and drug-coated balloons indicate a significant improvement in endovascular treatment durability and outcomes. This review provides an up-to-date assessment of the current evidence for the use of drug-coated stents and drug-coated balloons in the treatment of femoropopliteal and infrapopliteal peripheral artery disease. Additionally, it provides an overview of the development of this technology, highlights landmark ongoing and completed clinical trials, examines evidence to support the use of drug-coated technologies in combination with other modalities, and examines promising new technological developments. Last, it summarizes the challenges and safety concerns that have delayed U.S. Food and Drug Administration approval of these devices.

KW - drug-coated balloons

KW - drug-coated stents

KW - peripheral artery disease

KW - review

UR - http://www.scopus.com/inward/record.url?scp=84906347752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906347752&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2014.05.008

DO - 10.1016/j.jcin.2014.05.008

M3 - Article

C2 - 25147028

AN - SCOPUS:84906347752

VL - 7

SP - 827

EP - 839

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 8

ER -